Who are Ro 42-5892's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tekturna, Capozide 25/15, Aliskiren, Perindopril, Valsartan/aliskiren, Aliskiren Hydrochlorothiazide, Renin-Angiotensin (RAAS) alone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/remikiren.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ro 42-5892 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ro 42-5892 (REMIKIREN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: remikiren. Area: Cardiovascular.

phase 2 remikiren Renin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ro 42-5892 (REMIKIREN). Remikiren works by directly inhibiting the renin enzyme, which plays a key role in the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ro 42-5892 TARGET	REMIKIREN		phase 2	remikiren	Renin
Tekturna	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Aliskiren, Perindopril	Aliskiren, Perindopril	Medical University of Gdansk	marketed	Antihypertensive combination (direct renin inhibitor + ACE inhibitor)	Renin and Angiotensin-Converting Enzyme (ACE)
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)
Aliskiren Hydrochlorothiazide	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
Renin-Angiotensin (RAAS) alone	Renin-Angiotensin (RAAS) alone	James A. Tumlin, MD	marketed	RAAS inhibitor (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)	Renin-angiotensin-aldosterone system components (ACE, AT1 receptor, renin, or aldosterone receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (remikiren class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ro 42-5892 — Competitive Intelligence Brief. https://druglandscape.com/ci/remikiren. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing